Centre to review FDI policy in pharma on Monday

November 22, 2013 10:34 pm | Updated December 04, 2021 11:07 pm IST - NEW DELHI:

The government will take up on Monday the issue of tightening foreign direct investment (FDI) in existing pharmaceutical companies in the wake of concerns over multinationals taking over domestic drug makers.

“The Cabinet will review the FDI policy in the pharmaceutical sector on Monday,” an official said.

The Department of Industrial Policy and Promotion (DIPP) has proposed to reduce the FDI cap from 100 per cent to 49 per cent in the “rare or critical pharma verticals.”

It has also proposed to incorporate conditions for foreign firms like mandatory investment in R&D and non-compete clause in the shareholders pact.

As per the proposal, sources said, the foreign company would not be allowed to close down the existing R&D centre, and would have to mandatorily invest up to 25 per cent of FDI in the new unit or in the R&D facility. The total investment, as per the condition proposed, would have to be incurred within three years of the acquisition.

Sources said that there was a feeling in the government circle that with MNCs taking control of domestic firms, there could be reduction in supply of vaccines, injectables, particularly for cancer and active pharmaceutical ingredients.

“MNCs, which are acquiring domestic firms, have spent less than one per cent of their total sales in R&D in India. They are doing only clinical trials in India and not actual drug development work,” another source said.

Global firms are accusing India that its pharma policy is not in compliance with the international standards.

At present, the government permits 100 per cent FDI in the pharma sector through the automatic approval route in new projects but foreign investment in existing pharma companies are allowed only through FIPB nod.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.